MarlanaMariaOrloffMD

Oncology • Philadelphia, PA

Hematologic Oncology, Melanoma

Assistant Professor

Join to view full profile

Dr. Orloff is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Orloff's full profile

Already have an account?

Office
925 Chestnut St
Ste 320A
Philadelphia, PA 19107
Phone+1 215-955-1175

Fax+1 215-955-2340

Education & Training

Sidney Kimmel Medical College at Thomas Jefferson University/TJUHFellowship, Hematology and Medical Oncology, 2012 - 2015
Sidney Kimmel Medical College at Thomas Jefferson University/TJUHResidency, Internal Medicine, 2009 - 2012
Pennsylvania State University College of MedicineClass of 2009

Certifications & Licensure

DE State Medical License 2017 - 2025
NJ State Medical License 2017 - 2025
PA State Medical License 2009 - 2024
American Board of Internal Medicine Medical Oncology

Clinical Trials

Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver Start of enrollment: 2018 May 02
Active, not recruiting
Phase 2
A Prospective Natural History Study in Uveal Melanoma Start of enrollment: 2021 May 06
Recruiting
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions Start of enrollment: 2019 Jun 28
Recruiting
Phase 1, Phase 2
Roles: Contact
Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma Start of enrollment: 2021 Aug 02
Active, not recruiting
Phase 1
Roles: Contact, Principal Investigator
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma Start of enrollment: 2023 Oct 31
Recruiting
Phase 2, Phase 3
Roles: Contact
(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma Start of enrollment: 2023 Jul 03
Recruiting
Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

70 citations
Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immu...
Jason Chesney, Karl D Lewis, Harriet Kluger, Omid Hamid, Eric Whitman
Journal for Immunotherapy of Cancer. 2022-12-01
206 citations
CHECKPOINT INHIBITOR IMMUNE THERAPY: Systemic Indications and Ophthalmic Side Effects.
Lauren A Dalvin, Carol L. Shields, Marlana Orloff, Takami Sato, Jerry A. Shields
Retina. 2018-06-01
3 citations
Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicent...
Jonathan S Zager, Marlana Orloff, Pier Francesco Ferrucci, Junsung Choi, David J Eschelman
Annals of Surgical Oncology. 2024-08-01

Press Mentions

TriSalus Life Sciences Expands Clinical Executive Team and Scientific Advisors in Support of Company’s Focus to Overcome Liver and Pancreatic Cancer Treatment Barriers and Enable More Patients to Benefit from ImmunotherapyFebruary 10th, 2022
Metastatic Uveal Melanoma: New Drugs in Pipeline, but Prognoses Remain GrimDecember 14th, 2021
TriSalus Life Sciences Announces First Patient Enrolled in PERIO-01 Clinical Trial to Evaluate Delivery of SD-101 via Pressure-Enabled Drug Delivery in Uveal Melanoma Liver MetastasesSeptember 7th, 2021
Join now to see all

External Links

Jefferson Linkhttp://hospitals.jefferson.edu/find-a-doctor/o/orloff-marlana-m/